Clinical trial
A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the…
NCT00492297 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00492297 |
|---|---|
| Title | A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma |
| Official title | A Phase II, Multi-center, Open-label, Uncontrolled Study to Evaluate the Efficacy and Safety of BAY 43-9006 Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma. |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Melanoma |
| Intervention type | Drug |
| Interventions | Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC) |
| Enrollment | 83 |
| Start date | Apr 1, 2005 |
| Primary completion | Jun 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Jun 27, 2007 |
| Last update posted | Oct 31, 2014 |
| Countries | France, United Kingdom |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: